TY  - JOUR
T1  - Radiotherapy Outcomes and Prognostic Factors in Patients with Soft Tissue Sarcoma
TT  - Yumuşak Doku Sarkomu Olan Hastalarda Radyoterapi Sonuçları ve Prognostik Faktörler
AU  - Rakici, Sema
AU  - Altmışdörtoğlu, Özgür
PY  - 2025
DA  - July
Y2  - 2025
JF  - Rize Tıp Dergisi
JO  - RMJ
PB  - Recep Tayyip Erdoğan Üniversitesi
WT  - DergiPark
SN  - 2791-7231
SP  - 19
EP  - 28
VL  - 1
IS  - 1
LA  - en
AB  - Objective: We retrospectively evaluated treatment outcomes and prognostic factors in 86 patients with soft tissue sarcoma treated with postoperative or primary radiotherapy.Materials and Methods: Patients with soft tissue sarcoma who received postoperative or primary RT were retrospectively evaluated. Parameters such as stage, location, histopathological type, tumor size, surgical features, chemotherapy status and radiotherapy dose/fractionation were evaluated in terms of prognostic value of the disease.Results: The median age of the patients was 45 years (18-80), 45 (52%) were male and 41 (48%) were female. The median dose of radiotherapy was 60 (40-70) Gy at 1.8-2 Gy/ fraction. The median follow-up period was 53 (3-246 months) months. Five-year overall survival, disease-free survival and local control were 68%, 61% and 76%, respectively. In univariate analysis, tumor size >10 cm (p=0.01), deep location (p=0.001), grade III-IV (p=0.0001), stage III (p=0.02) and (+) surgical margin (p=0.002) for OS, grade III-IV (p=0.0001), stage III (p=0. 030) and (+) surgical margin (p=0.012); for local control, tumor localization (extremity vs other) (p=0.028), grade III-IV (p=0.004), depth (p=0.035) and (+) surgical margin (p
KW  - Grade
KW  - local control
KW  - prognostic factor
KW  - radiotherapy
KW  - soft tissue sarcoma.
N2  - Objective: We retrospectively evaluated treatment outcomes and prognostic factors in 86 patients with soft tissue sarcoma treated with postoperative or primary radiotherapy.Materials and Methods: Patients with soft tissue sarcoma who received postoperative or primary RT were retrospectively evaluated. Parameters such as stage, location, histopathological type, tumor size, surgical features, chemotherapy status and radiotherapy dose/fractionation were evaluated in terms of prognostic value of the disease.Results: The median age of the patients was 45 years (18-80), 45 (52%) were male and 41 (48%) were female. The median dose of radiotherapy was 60 (40-70) Gy at 1.8-2 Gy/ fraction. The median follow-up period was 53 (3-246 months) months. Five-year overall survival, disease-free survival and local control were 68%, 61% and 76%, respectively. In univariate analysis, tumor size >10 cm (p=0.01), deep location (p=0.001), grade III-IV (p=0.0001), stage III (p=0.02) and (+) surgical margin (p=0.002) for OS, grade III-IV (p=0.0001), stage III (p=0. 030) and (+) surgical margin (p=0.012); for local control, tumor localization (extremity vs other) (p=0.028), grade III-IV (p=0.004), depth (p=0.035) and (+) surgical margin (p
CR  - 1.      Karakousis CP, Perez RP. Soft tissue sarcomas in adults. CA: a cancer journal for clinicians. 1994;44(4):200-210.
CR  - 2.	Ferrari A, Sultan I, Huang TT, et al. Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatric blood & cancer. 2011;57(6):943-949.
CR  - 3.	Penel N, Grosjean J, Robin YM, et al. Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases. Sarcoma. 2008;2008:459386.
CR  - 4.	Demetri GD, Baker LH, Beech D, et al. Soft tissue sarcoma clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2005;3(2):158-194.
CR  - 5.	Serban B, Cretu B, Cursaru A, et al. Local recurrence management of extremity soft tissue sarcoma. EFORT open reviews. 2023;8(8):606-614.
CR  - 6.	Park D. Yasal/Özel Etik Kurul İzin Belgesi Alınması 2025 [Available from: https://dergipark.org.tr/tr/pub/ibad/page/9412.
CR  - 7.	Steen S, Stephenson G. Current treatment of soft tissue sarcoma. Proceedings Baylor University Medical Center. 2008;21(4):392-396.
CR  - 8.	Nedea EA, DeLaney TFJHOC. Sarcoma and skin radiation oncology. 2006;20(2):401-429.
CR  - 9.	Cosci I, Del Fiore P, Mocellin S, et al. Gender Differences in Soft Tissue and Bone Sarcoma: A Narrative Review. Cancers. 2023;16(1).
CR  - 10.	Katz D, Palmerini E, Pollack SM. More Than 50 Subtypes of Soft Tissue Sarcoma: Paving the Path for Histology-Driven Treatments. 2018(38):925-938.
CR  - 11.	Yildiz C, Erler K, Bilgiç S, et al. The effects of surgical margins on local control and survival in extremity soft tissue sarcomas. Acta orthopaedica et traumatologica turcica. 2003;37(5):359-367.
CR  - 12.	O'Donnell PW, Griffin AM, Eward WC, et al. The effect of the setting of a positive surgical margin in soft tissue sarcoma. 2014;120(18):2866-2875.
CR  - 13.	Cheng EYJHOC. Surgical management of sarcomas. 2005;19(3):451-470.
CR  - 14.	Eilber FC, Eilber FR, Eckardt J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Annals of surgery. 2004;240(4):686-695; discussion 695-687.
CR  - 15.	Rakici SY, Çinar Y, Eren M. Total scalp irradiation: the comparison of five different plans using volumetric modulated arc therapy-simultaneous integrated boost (VMAT-SIB) technique. 2017;32(3).
CR  - 16.	Schwartz DL, Einck J, Hunt K, et al. The effect of delayed postoperative irradiation on local control of soft tissue sarcomas of the extremity and torso. Int J Radiat Oncol Biol Phys. 2002;52(5):1352-1359.
UR  - https://dergipark.org.tr/tr/pub/rizetip/issue//1634145
L1  - https://dergipark.org.tr/tr/download/article-file/4583848
ER  -